Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 473 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in... March 15, 2023 The most important cancer research stories of 2022 December 14, 2022 EMA Recommends Extension of Therapeutic Indications for Ponatinib February 27, 2026 Load more HOT NEWS Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to... “Giving something back”: our supporters are the beating heart of what... New chemotherapy-free treatment for bowel cancer made available in Scotland EMA Recommends Granting a Marketing Authorisation for Capmatinib
